Investor Presentaiton
•
Mithra at a glance
Global women's health company
O Liege, Belgium
Founded in 1999
Listed on Euronext Brussels in 2015:
MITRA
Innovative Estetrol products
О Native estrogen
Differentiated benefit/risk profile
compared to existing hormone-based
solutions
ESTELLEⓇ, a new contraceptive
DONESTAⓇ, potential treatment for
menopausal symptoms & better aging
Innovative pipeline expansion
Novalon (complex therapeutics) & CDMO
Commercial
Development/
Performance in
H1 2023
-50.5
million
EUR net loss
2.6
million
EUR Product sales
of ESTELLE®
51
million
EUR Milestones
collected
634,000
MYRINGⓇ vaginal
rings produced at
our CDMO
Dedicated to
Mithra as a
company
transforming
women's health
Positive
Top-line safety
results for
DONESTAⓇ Phase
III (C302)
30
Countries in which
our contraceptive
pill ESTELLEⓇ is
commercialized
(+19 vs 2022)
1999
Founded
Since 2015
Listed on Euronext
Brussels
38
R&D collaborators
among 233
dedicated
36
employees
Patents covering
E4
56%
Women employees
How we drive our
business to lower
impact on
environment &
society (ESG)
-22%
Reduction in
Greenhouse gas
emission (target-
55% by 2030)
100%
Successful
inspections and
customer audits
55%
Women in
leadership posts
(CEO N -2)
Mithra Investor Presentation - November 2023
6View entire presentation